Table of Contents
Thrombosis
Volume 2014, Article ID 714218, 14 pages
http://dx.doi.org/10.1155/2014/714218
Review Article

Advances in Medical Revascularisation Treatments in Acute Ischemic Stroke

1Melbourne Brain Centre, Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia
2Radiology Department, Western Hospital, Footscray, VIC, Australia

Received 5 September 2014; Accepted 17 December 2014; Published 30 December 2014

Academic Editor: David H. Farrell

Copyright © 2014 H. Asadi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Ferrell and G. W. Britz, “Developments on the horizon in the treatment of neurovascular problems,” Surgical Neurology International, vol. 4, supplement 1, pp. S31–S37, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. K. A. Blackham, P. M. Meyers, T. A. Abruzzo et al., “Endovascular therapy of acute ischemic stroke: report of the standards of practice committee of the society of neuroInterventional surgery,” Journal of NeuroInterventional Surgery, vol. 4, no. 2, pp. 87–93, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Lloyd-Jones, R. Adams, M. Carnethon et al., “Heart disease and stroke statistics—2009 update: a report from the American heart association statistics committee and stroke statistics subcommittee,” Circulation, vol. 119, no. 3, pp. 480–486, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Hacke, A. J. Furlan, Y. Al-Rawi et al., “Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study,” The Lancet Neurology, vol. 8, no. 2, pp. 141–150, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. S. M. Adelman, “The national survey of stroke. Economic impact,” Stroke, vol. 12, supplement 1, no. 2, pp. I-69–I-87, 1981. View at Google Scholar · View at Scopus
  6. T. N. Taylor, P. H. Davis, J. C. Torner, J. Holmes, J. W. Meyer, and M. F. Jacobson, “Lifetime cost of stroke in the United States,” Stroke, vol. 27, no. 9, pp. 1459–1466, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. W. Rosamond, K. Flegal, G. Friday et al., “Heart disease and stroke statistics—2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee,” Circulation, vol. 115, no. 5, pp. e69–e171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. R. G. González, W. A. Copen, P. W. Schaefer et al., “The Massachusetts General Hospital acute stroke imaging algorithm: an experience and evidence based approach,” Journal of NeuroInterventional Surgery, vol. 5, supplement 1, pp. i7–i12, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. J.-H. Rha and J. L. Saver, “The impact of recanalization on ischemic stroke outcome: a meta-analysis,” Stroke, vol. 38, no. 3, pp. 967–973, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Meretoja, M. Keshtkaran, J. L. Saver et al., “Stroke thrombolysis: save a minute, save a day,” Stroke, vol. 45, no. 4, pp. 1053–1058, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Eissa, I. Krass, C. Levi, J. Sturm, R. Ibrahim, and B. Bajorek, “Understanding the reasons behind the low utilisation of thrombolysis in stroke,” Australasian Medical Journal, vol. 6, no. 3, pp. 152–163, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. K. R. Lees, E. Bluhmki, R. von Kummer et al., “Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials,” The Lancet, vol. 375, no. 9727, pp. 1695–1703, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Ebinger, B. Winter, M. Wendt et al., “Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial,” Journal of the American Medical Association, vol. 311, no. 16, pp. 1622–1631, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. A. J. Furlan, D. Eyding, G. W. Albers et al., “Dose escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset,” Stroke, vol. 37, no. 5, pp. 1227–1231, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. H. P. Adams Jr., G. del Zoppo, M. J. Alberts et al., “Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists,” Circulation, vol. 115, no. 20, pp. e478–534, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. “Tissue plasminogen activator for acute ischemic stroke,” New England Journal of Medicine, vol. 333, no. 24, pp. 1581–1587, 1995.
  17. W. Hacke, M. Kaste, E. Bluhmki et al., “Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke,” The New England Journal of Medicine, vol. 359, no. 13, pp. 1317–1329, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Sandercock, J. M. Wardlaw, R. I. Lindley et al., “The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial,” The Lancet, vol. 379, no. 9834, pp. 2352–2363, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. N. Ahmed, L. Kellert, K. R. Lees, R. Mikulik, T. Tatlisumak, and D. Toni, “Results of intravenous thrombolysis within 4.5 to6hours and updatedresults within 3 to 4.5 hours of onset ofacute ischemic strokerecorded in the safe implementation of treatment in stroke international stroke thrombolysis register (SITS-ISTR): an observational study,” JAMA Neurology, vol. 70, no. 7, pp. 837–844, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. S. M. Zinkstok and Y. B. Roos, “Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trial,” The Lancet, vol. 380, no. 9843, pp. 731–737, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Parsons, N. Spratt, A. Bivard et al., “A randomized trial of tenecteplase versus alteplase for acute ischemic stroke,” The New England Journal of Medicine, vol. 366, no. 12, pp. 1099–1107, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. W. Hacke, G. Albers, Y. Al-Rawi et al., “The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase,” Stroke, vol. 36, no. 1, pp. 66–73, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. D. G. Sherman, R. P. Atkinson, T. Chippendale et al., “Intravenous ancrod for treatment of acute ischemic stroke. the STAT study: a randomized controlled trial,” Journal of the American Medical Association, vol. 283, no. 18, pp. 2395–2403, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Siebler, M. G. Hennerici, D. Schneider et al., “Safety of tirofiban in acute ischemic stroke: the SaTIS trial,” Stroke, vol. 42, no. 9, pp. 2388–2392, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. H. P. Adams Jr., M. B. Effron, J. Torner et al., “Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II),” Stroke, vol. 39, no. 1, pp. 87–99, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. A. M. Pancioli, O. Adeoye, P. A. Schmit et al., “Combined approach to lysis utilizing eptifibatide and recombinant tissue plasminogen activator in acute ischemic stroke-enhanced regimen stroke trial,” Stroke, vol. 44, no. 9, pp. 2381–2387, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. M. P. LaMonte, M. L. Nash, D. Z. Wang et al., “Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study,” Stroke, vol. 35, no. 7, pp. 1677–1682, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. A. D. Barreto, A. V. Alexandrov, P. Lyden et al., “The Argatroban and tissue-type plasminogen activator stroke study: final results of a pilot safety study,” Stroke, vol. 43, no. 3, pp. 770–775, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. M. G. Lansberg, M. Straka, S. Kemp et al., “MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): a prospective cohort study,” The Lancet Neurology, vol. 11, no. 10, pp. 860–867, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. G. W. Albers, V. N. Thijs, L. Wechsler et al., “Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study,” Annals of Neurology, vol. 60, no. 5, pp. 508–517, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. S. M. Davis, G. A. Donnan, M. W. Parsons et al., “Effects of alteplase beyond 3 h after stroke in the echoplanar imaging thrombolytic evaluation trial (EPITHET): a placebo-controlled randomised trial,” The Lancet Neurology, vol. 7, no. 4, pp. 299–309, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. A. V. Alexandrov, C. A. Molina, J. C. Grotta et al., “Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke,” The New England Journal of Medicine, vol. 351, no. 21, pp. 2170–2178, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. C. A. Molina, A. D. Barreto, G. Tsivgoulis et al., “Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial,” Annals of Neurology, vol. 66, no. 1, pp. 28–38, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. G. J. del Zoppo, J. L. Saver, E. C. Jauch, and H. P. Adams Jr., “Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American heart association/american stroke association,” Stroke, vol. 40, no. 8, pp. 2945–2948, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal, “Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy,” Chest, vol. 126, supplement 3, pp. 483S–512S, 2004. View at Publisher · View at Google Scholar · View at Scopus
  36. C. A. Molina and J. L. Saver, “Extending reperfusion therapy for acute ischemic stroke: emerging pharmacological, mechanical, and imaging strategies,” Stroke, vol. 36, no. 10, pp. 2311–2320, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. A. D. Barreto and A. V. Alexandrov, “Adjunctive and alternative approaches to current reperfusion therapy,” Stroke, vol. 43, no. 2, pp. 591–598, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. R. Mikulík, M. Dufek, D. Goldemund, and M. Reif, “A pilot study on systemic thrombolysis followed by low molecular weight heparin in ischemic stroke,” European Journal of Neurology, vol. 13, no. 10, pp. 1106–1111, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. S. M. Zinkstok, M. Vermeulen, J. Stam, R. J. de Haan, and Y. B. Roos, “A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial,” Trials, vol. 11, article 51, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. G. J. del Zoppo, R. T. Higashida, A. J. Furlan, M. S. Pessin, H. A. Rowley, and M. Gent, “PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke,” Stroke, vol. 29, no. 1, pp. 4–11, 1998. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Furlan, R. Higashida, L. Wechsler et al., “Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial,” Journal of the American Medical Association, vol. 282, no. 21, pp. 2003–2011, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Yepes, B. D. Roussel, C. Ali, and D. Vivien, “Tissue-type plasminogen activator in the ischemic brain: more than a thrombolytic,” Trends in Neurosciences, vol. 32, no. 1, pp. 48–55, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. E. C. Haley, J. L. P. Thompson, J. C. Grotta et al., “Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial,” Stroke, vol. 41, no. 4, pp. 707–711, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. E. C. Haley Jr., P. D. Lyden, K. C. Johnston, and T. M. Hemmen, “A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke,” Stroke, vol. 36, no. 3, pp. 607–612, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. D. Smadja, N. Chausson, J. Joux et al., “A new therapeutic strategy for acute ischemic stroke: sequential combined intravenous tpa-tenecteplase for proximal middle cerebral artery occlusion based on first results in 13 consecutive patients,” Stroke, vol. 42, no. 6, pp. 1644–1647, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. N. Logallo, C. E. Kvistad, A. Nacu et al., “The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke,” BMC Neurology, vol. 14, no. 1, article 106, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. R. von Kummer, G. W. Albers, E. Mori et al., “The desmoteplase in acute ischemic stroke (DIAS) clinical trial program,” International Journal of Stroke, vol. 7, no. 7, pp. 589–596, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. J. F. Kirmani, A. Alkawi, S. Panezai, and M. Gizzi, “Advances in thrombolytics for treatment of acute ischemic stroke,” Neurology, vol. 79, no. 13, supplement 1, pp. S119–S125, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. D. E. Levy, G. J. Del Zoppo, B. M. Demaerschalk et al., “Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program,” Stroke, vol. 40, no. 12, pp. 3796–3803, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. M. G. Hennerici, R. Kay, J. Bogousslavsky, G. L. Lenzi, M. Verstraete, and J. M. Orgogozo, “Intravenous ancrod for acute ischaemic stroke in the European stroke treatment with ancrod trial: a randomised controlled trial,” The Lancet, vol. 368, no. 9550, pp. 1871–1878, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. M. G. Hennerici, R. Kay, J. Bogousslavsky, G. L. Lenzi, M. Verstraete, and J. M. Orgogozo, “Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial,” The Lancet, vol. 368, no. 9550, pp. 1871–1878, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. P. R. Eisenberg, B. E. Sobel, and A. S. Jaffe, “Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator,” Journal of the American College of Cardiology, vol. 19, no. 5, pp. 1065–1069, 1992. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Pereira, “Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial,” Revista Portuguesa de Cardiologia, vol. 20, no. 6, pp. 687–688, 2001. View at Google Scholar · View at Scopus
  54. E. M. Ohman, N. S. Kleiman, G. Gacioch et al., “Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: results of a randomized, placebo-controlled, dose- ranging trial,” Circulation, vol. 95, no. 4, pp. 846–854, 1997. View at Publisher · View at Google Scholar · View at Scopus
  55. G. Torgano, B. Zecca, V. Monzani et al., “Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial,” Cerebrovascular Diseases, vol. 29, no. 3, pp. 275–281, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. I. K. Jang, D. F. M. Brown, R. P. Giugliano et al., “A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study,” Journal of the American College of Cardiology, vol. 33, no. 7, pp. 1879–1885, 1999. View at Publisher · View at Google Scholar · View at Scopus
  57. H. Kawai, K. Umemura, and M. Nakashima, “Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model,” Japanese Journal of Pharmacology, vol. 69, no. 2, pp. 143–148, 1995. View at Publisher · View at Google Scholar · View at Scopus
  58. D. C. Morris, L. Zhang, Z. G. Zhang et al., “Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke,” Stroke, vol. 32, no. 11, pp. 2635–2640, 2001. View at Publisher · View at Google Scholar · View at Scopus
  59. R. M. Sugg, J. K. Pary, K. Uchino et al., “Argatroban tPA stroke study: study design and results in the first treated cohort,” Archives of Neurology, vol. 63, no. 8, pp. 1057–1062, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. A. D. Barreto, “Randomized controlled trial of argatroban with tPA for acute stroke (ARTSS-2),” in ClinicalTrials.gov, National Library of Medicine (US), Bethesda, Md, USA, 2011, https://clinicaltrials.gov/show/NCT01464788. View at Google Scholar
  61. G. J. del Zoppo, K. Poeck, M. S. Pessin et al., “Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke,” Annals of Neurology, vol. 32, no. 1, pp. 78–86, 1992. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Saqqur, K. Uchino, A. M. Demchuk et al., “Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke,” Stroke, vol. 38, no. 3, pp. 948–954, 2007. View at Publisher · View at Google Scholar · View at Scopus
  63. C. A. Molina, J. Montaner, J. F. Arenillas, M. Ribo, M. Rubiera, and J. Alvarez-Sabín, “Differential pattern of tissue plasminogen activator-induced proximal middle cerebral artery recanalization among stroke subtypes,” Stroke, vol. 35, no. 2, pp. 486–490, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. C. H. Riedel, P. Zimmermann, U. Jensen-Kondering, R. Stingele, G. Deuschl, and O. Jansen, “The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length,” Stroke, vol. 42, no. 6, pp. 1775–1777, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Rubiera, J. Alvarez-Sabín, M. Ribo et al., “Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke,” Stroke, vol. 36, no. 7, pp. 1452–1456, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. H. Ma, M. W. Parsons, S. Christensen et al., “A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND),” International Journal of Stroke, vol. 7, no. 1, pp. 74–80, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. G. Thomalla, “Efficacy and safety of MRI-based thrombolysis in wake-up stroke (WAKE-UP),” in ClinicalTrials.gov [Internet], National Library of Medicine (US), Bethesda, Md, USA, 2014, NLM Identifier: NCT01525290, http://clinicaltrials.gov/show/NCT01525290. View at Google Scholar
  68. J. A. Álvarez-Fernández, “Ultrasound-enhanced systemic thrombolysis. An effective and underutilized treatment for acute ischemic stroke,” Medicina Intensiva, vol. 35, no. 2, pp. 134–135, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. M. Daffertshofer, A. Gass, P. Ringleb et al., “Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: Increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial,” Stroke, vol. 36, no. 7, pp. 1441–1446, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. “Cerevast. Phase 3, randomized, placebo-controlled, double-blinded trial of the combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator (tPA) for emergent revascularization in acute ischemic stroke (CLOTBUST-ER),” in ClinicalTrials.gov, National Library of Medicine (US), Bethesda, Md, USA, 2014, http://clinicaltrials.gov/show/NCT01098981.
  71. C. A. Molina, M. Ribo, M. Rubiera et al., “Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator,” Stroke, vol. 37, no. 2, pp. 425–429, 2006. View at Publisher · View at Google Scholar · View at Scopus